ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

Report of kick-off meeting

Report of kickoff meeting

Target product profile for stage-specific biomarkers - submitted to WHO and EMA

Target product profile for stage-specific biomarkers – submitted to WHO and EMA

Report of third annual consortium meeting
Communication and dissemination plan
Report of second annual consortium meeting
Annual report on status of posting results for phase 2B/C (1)
Establish CAG
Establish SAB and RAB
Annual report on status of posting results for phase 2A (1)
DAT training module developed
Report of first annual consortium meeting
Establish EAB
Code for pharmacodynamic models applicable phase 2A and 2B/C data (1)

Code for pharmacodynamic models applicable phase 2A and 2B/C data (1)

Inaugural meeting with communication professionals of the partners in the consortium
Establish Young Investigators Group

Visual identity and communication toolkit, including project website

Visual identity and communication toolkit including project website

Publications

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Auteurs: Keutzer L, You H, Farnoud A, Nyberg J, Wicha SG, Maher-Edwards G, Vlasakakis G, Moghaddam GK, Svensson EM, Menden MP, Simonsson USH, On Behalf Of The UNITE4TB Consortium
Publié dans: Pharmaceutics, 2022, ISSN 1999-4923
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14081530

A flexible multi‐metric Bayesian framework for decision‐making in Phase II multi‐arm multi‐stage studies

Auteurs: Suzanne M. Dufault; Angela M. Crook; Katie Rolfe; Patrick P. J. Phillips
Publié dans: Statistics in Medicine , 43 (3) pp. 501-513. (2024), Numéro 17, 2024, Page(s) 501-513, ISSN 0277-6715
Éditeur: John Wiley & Sons Inc.
DOI: 10.1002/sim.9961

Treatment-shortening regimens for tuberculosis: updates and future priorities

Auteurs: Francesca Saluzzo, Victor Abiola Adepoju, Raquel Duarte, Christoph Lange, Patrick P.J. Phillips
Publié dans: Breathe, Numéro 19 (3), October, 2023, ISSN 1810-6838
Éditeur: European Respiratory Society
DOI: 10.1183/20734735.0028-2023

Tuberculosis: current challenges and beyond

Auteurs: Raquel Villar-Hernández, Arash Ghodousi, Olha Konstantynovska, Raquel Duarte, Christoph Lange, Mario Raviglione on behalf of the UNITE4TB Consortium
Publié dans: Breath, 2023, ISSN 2073-4735
Éditeur: European Respiratory Society
DOI: 10.1183/20734735.0166-2022

Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis

Auteurs: Simone Villa, Pierpaolo de Colombani, Lucia Dall’Olio, Giuliano Gargioni, Mario Raviglione
Publié dans: BMJ Global Health, Numéro 2024;9: e014630, 2024, Page(s) 1-9, ISSN 2059-7908
Éditeur: BMJ Journals
DOI: 10.1136/bmjgh-2023-014630

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

Auteurs: Heyckendorf J, Georghiou SB, Frahm N, Heinrich N, Kontsevaya I, Reimann M, Holtzman D, Imperial M, Cirillo DM, Gillespie SH, Ruhwald M, Consortium UNITE4TB
Publié dans: Clinical Microbiology Reviews, Numéro 21 March 2022, 2022, Page(s) n/a, ISSN 1098-6618
Éditeur: American Society for Microbiology
DOI: 10.1128/cmr.00227-21

Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles 

Auteurs: Stephen H Gillespie , Andrew R DiNardo, Sophia B Georghiou, Wilber Sabiiti , Mikashmi Kohli, Ursula Panzner , Irina Kontsevaya6, Norbert Hittel, Lieven J Stuyver, Jia Bin Tan, Reinout van Crevel, Christoph Lange, Thuong Nguyen Thuy Thuong, Jan Heyckendorf, Morten Ruhwald, Norbert Heinrich
Publié dans: Lancet Microbe, 2024, Page(s) 1-11, ISSN 2666-5247
Éditeur: Elsevier ltd.
DOI: 10.1016/s2666-5247(24)00085-5

Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries

Auteurs: Anca Vasiliu, Antonia Morita Iswari Saktiawati, Raquel Duarte, Christoph Lange, Daniela Maria Cirillo on behalf of the UNITE4TB Consortium
Publié dans: Breath, 2023, ISSN 2073-4735
Éditeur: European Respiratory Society
DOI: 10.1183/20734735.0226-2022

Rolling out new anti-tuberculosis drugs without diagnostic capacity

Auteurs: Tara Ness, Le Hong Van, Ilze Petermane, Raquel Duarte, Christoph Lange, Dick Menzies, Daniela Maria Cirillo
Publié dans: Breathe, Numéro 19(2), July, 2023, ISSN 1810-6838
Éditeur: European Respiratory Society
DOI: 10.1183/20734735.0084-2023

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Auteurs: Mockeliunas L, Faraj A, van Wijk RC, Upton CM, van den Hoogen G, Diacon AH, Simonsson USH
Publié dans: Front. Pharmacol., 2023, ISSN 1663-9812
Éditeur: Frontiers Media S.A.
DOI: 10.3389/fphar.2023.1150243

UNITE4TB: a new consortium for clinical drug and regimen development for TB

Auteurs: Boeree, M. J.; Lange, C.; Thwaites, G; Paton, N ; de Vrueh, R.; Barros, D.; Hoelscher, M.; on behalf of the UNITE4TB Consortium
Publié dans: International Union Against Tuberculosis and Lung Disease, Numéro Volume 25, Number 11, 1 November 2021, 2021, Page(s) 886-889, ISSN 1027-3719
Éditeur: International Union Against Tuberculosis And Lung Disease/Union Internationale Contre la Tuberculose et les Maladies Respiratories
DOI: 10.5588/ijtld.21.0515

Recherche de données OpenAIRE...

Livrables

Publications

Partager cette page

Télécharger